Design and synthesis of novel hederagonic acid analogs as potent anti-inflammatory compounds capable of protecting against LPS-induced acute lung injury

Acute lung injury (ALI) presents a significant clinical challenge due to its high mortality rates and the lack of effective treatment strategies. The most effective approaches to treating ALI include disrupting inflammatory cascades and associated inflammatory damage within the lung. Hederagenin was utilized as a core skeleton to design and synthesize 33 hederagonic acid derivatives. Among these derivatives, compound 29 demonstrated potent anti-inflammatory activity without inducing cytotoxicity, inhibiting nitric oxide (NO) release by 78-86 %. Detailed structure-activity relationship studies and the reverse virtual screening of ALI-related targets revealed that compound 29 exhibits a high affinity for the STING protein. Mechanistic studies revealed that compound 29 suppresses macrophage activation, inhibits the nuclear translocation of IRF3 and p65, and disrupts the STING/ IRF3/NF-kappa B signaling pathway, thereby attenuating the inflammatory response. The in vivo administration of compound 29 was sufficient to protect against lipopolysaccharide (LPS)-induced ALI by suppressing the production of inflammatory mediators, including IL-6, TNF-alpha, and IFN-beta, thereby preserving lung tissue integrity. These results substantiate the anti-inflammatory efficacy of compound 29, both in vitro and in vivo, indicating its potential as a promising lead compound in ALI treatment strategies.